Genelux Corporation's CEO will discuss its lead candidate, Olvi-Vec, in a virtual session on December 16, 2024.
Quiver AI Summary
Genelux Corporation, a late clinical-stage immuno-oncology firm, announced that its President and CEO, Thomas Zindrick, will engage in a virtual fireside chat on December 16, 2024, with H.C. Wainwright & Co. The discussion, moderated by analyst Emily Bodnar, will focus on Genelux's lead candidate, Olvi-Vec, highlighting its ongoing clinical trials for various cancers, including a Phase 3 trial for platinum-resistant ovarian cancer and trials for small-cell and non-small cell lung cancer. Interested participants can register online, and an archived replay will be available afterward. Genelux specializes in developing innovative oncolytic immunotherapies, with Olvi-Vec being their most advanced candidate.
Potential Positives
- Participation of the CEO in a fireside chat indicates active engagement with the investment community, which can enhance investor confidence.
- Focus on clinical trials of the lead candidate, Olvi-Vec, highlights ongoing development in significant cancer therapies, potentially attracting interest from investors and partners.
- The availability of a replay of the event for 90 days allows for broader accessibility, which may engage more stakeholders in the company’s progress.
Potential Negatives
- Participation in a virtual fireside chat may indicate that the company is seeking to generate investor interest amid uncertainty or low visibility in its clinical trials, suggesting potential challenges ahead.
- The emphasis on ongoing clinical trials without any recent positive data updates may raise concerns about the progress and success of these trials, affecting investor confidence.
- The focus on a niche market (platinum resistant/refractory ovarian cancer) could suggest limitations in market potential compared to broader treatment options, which may impact future growth prospects.
FAQ
What is the date and time of the virtual fireside chat?
The virtual fireside chat will take place on December 16, 2024, at 11:00 a.m. ET.
Who will be moderating the fireside chat?
The fireside chat will be moderated by Emily Bodnar, a Biotech Equity Research Analyst at H.C. Wainwright & Co.
What is the focus of the upcoming discussion?
The discussion will focus on Genelux's clinical program and its lead candidate, Olvi-Vec, including ongoing trials in cancer.
How can I register for the virtual event?
You can register for the event at https://ct.to/n900Z9K.
Will there be a replay of the event available?
An archived replay of the event will be available for approximately 90 days on the company’s Investor Relations page.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GNLX Insider Trading Activity
$GNLX insiders have traded $GNLX stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $GNLX stock by insiders over the last 6 months:
- ALADAR SZALAY has traded it 11 times. They made 0 purchases and 11 sales, selling 540,000 shares.
- JAMES L TYREE sold 1,730 shares.
- YONG YU (VP, Clinical Trial Operations) sold 6,849 shares.
- SEAN RYDER (General Counsel) sold 5,496 shares.
- CAROLINE JEWETT (Head of Quality) sold 4,961 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$GNLX Hedge Fund Activity
We have seen 21 institutional investors add shares of $GNLX stock to their portfolio, and 57 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 900,000 shares (-100.0%) from their portfolio in Q3 2024
- HIGHBRIDGE CAPITAL MANAGEMENT LLC removed 631,307 shares (-100.0%) from their portfolio in Q3 2024
- GOLDMAN SACHS GROUP INC removed 180,245 shares (-100.0%) from their portfolio in Q3 2024
- BLACKROCK, INC. removed 97,986 shares (-24.0%) from their portfolio in Q3 2024
- NORTHERN TRUST CORP removed 97,589 shares (-67.2%) from their portfolio in Q3 2024
- MARSHALL WACE, LLP added 93,100 shares (+931.0%) to their portfolio in Q3 2024
- WOODWARD DIVERSIFIED CAPITAL, LLC added 92,896 shares (+7.4%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) --
Genelux Corporation
(NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that
Thomas Zindrick
, President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024.
Biotech Equity Research Analyst, Emily Bodnar, will moderate the HCW@Home session which is scheduled to begin at 11:00 a.m. ET. The discussion will focus on the company’s clinical program of its lead candidate, Olvi-Vec, including its ongoing Phase 3 registration trial in platinum resistant/refractory ovarian cancer (PRROC), Phase 1b/2 trial in small-cell lung cancer (SCLC) and Phase 2 trial in non-small cell lung cancer (NSCLC). To join, please register at
https://ct.to/n900Z9K
. An archived replay will be available for approximately 90 days following the event on the company’s IR page.
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company's most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit
www.genelux.com
and follow us on Twitter
@Genelux_Corp
and on
LinkedIn
.
Investor and Media Contacts
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
Source: Genelux Corporation
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
